Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

In search of Marcel Proust's lost health

A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...

J&J utökar cancerportföljen – köper Halda för 33 miljarder

Johnson & Johnson (J&J) stärker sin ställning inom cancerområdet genom att köpa det privatägda Halda Therapeutics för motsvarande 33 miljarder kronor. Affären ä...

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

Wegovy approved in the U.S. for treatment of liver disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...

Carl Zeiss Meditec achieves revenue growth and stable operating profit

Further recovery in order entry compared to prior year.

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Studie: Biomarkörer förutser hjärt-kärlkomplikationer vid typ 2-diabetes

Epigenetiska biomarkörer kan förutsäga vilka personer med typ 2-diabetes som riskerar att få hjärt-kärlsjukdomar, enligt en ny studie från Lunds universitet.

Quality assurance for research and development of medical devices

Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.

Billion-Dollar Deal Sends BioArctic Soaring

Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

ZEISS Metrology Expert Tips

New video series provides valuable expert knowledge.

Ny behandling för dödlig lungsjukdom – första på ett decennium

För första gången på över tio år har nu ett nytt läkemedel godkänts mot den svårbehandlade lungsjukdomen idiopatisk lungfibros, IPF.

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

The Future of Swedish & Danish Life Science (2026)

Alzecure får patent i Japan för läkemedelskandidat

Alzecure Pharmas läkemedelskandidat, ACD856, för behandling av Alzheimer har beviljats patent av det japanska patentverket.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

New Insights into Microscopy

Watch the recording of our free webinar.

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Neogap värvar tungt namn inom cellterapi

Bioteknikbolaget Neogap Therapeutics fyller på styrelsen med expertis inom cellterapi i form av professor Jonas Mattsson.